Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 2/20 | 0.33 |
| ▸ | TERT | O14746 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10283909 | 0.84 | KMT2A (0.35) | KMT2AMCL1KDM4EALDH1A1TSHR | |
| SCHEMBL9887744 | 0.75 | KMT2A (0.55) | KMT2AMCL1DAOTERTKDM4E | |
| SCHEMBL7756916 | 0.75 | KDM4E (0.42) | KMT2AMCL1DAOKDM4EALDH1A1 | |
| SCHEMBL14929532 | 0.74 | KMT2A (0.59) | KMT2AKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL26596972 | 0.73 | KMT2A (0.36) | KMT2AMCL1DAOTERTKDM4E | |
| SCHEMBL28127160 | 0.73 | KMT2A (0.40) | KMT2AMCL1DAOTERTKDM4E | |
| SCHEMBL13236070 | 0.73 | HSD17B10 (0.41) | KMT2AMCL1KDM4EALDH1A1TSHR | |
| SCHEMBL18511093 | 0.73 | KMT2A (0.40) | KMT2AMCL1DAOTERTKDM4E | |
| SCHEMBL7638728 | 0.73 | HDAC10 (0.40) | KMT2AMCL1DAOTERTKDM4E | |
| SCHEMBL3968278 | 0.73 | KMT2A (0.40) | KMT2AMCL1DAOTERTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11584751-B1 | Substituted imidazoles as GLP-1 receptor agonists | ECCOGENE (SHANGHAI) CO., LTD. (CN) | 2023-02-21 | — | — | US | disclosed |
| WO-2020123670-A1 | SMALL MOLECULE INHIBITORS OF THE ANDROGEN RECEPTOR ACTIVITY AND/OR EXPRESSION AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2020-06-18 | — | — | WO | disclosed |
| US-9409938-B2 | Tungsten oxo alkylidene complexes for Zselective olefin metathesis | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2016-08-09 | — | — | US | disclosed |
| US-20160009746-A1 | TUNGSTEN OXO ALKYLIDENE COMPLEXES FOR Z SELECTIVE OLEFIN METATHESIS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2016-01-14 | — | — | US | disclosed |
| US-9085595-B2 | Tungsten oxo alkylidene complexes for Z selective olefin metathesis | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2015-07-21 | — | — | US | disclosed |
| US-20130116434-A1 | TUNGSTEN OXO ALKYLIDENE COMPLEXES FOR Z SELECTIVE OLEFIN METATHESIS | TRUSTEES OF BOSTON COLLEGE (US) | 2013-05-09 | — | — | US | disclosed |
| US-8093254-B2 | Aspartyl protease inhibitors | SCHERING CORPORATION (US) | 2012-01-10 | — | — | US | disclosed |
| US-20100069406-A1 | ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION (US) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584751-B1 | Substituted imidazoles as GLP-1 receptor agonists | GLP1R, GIPR, SLC5A1 | KMT2A 3521/4885MCL1 3399/4885DAO 1821/4885 |
| US-20130116434-A1 | TUNGSTEN OXO ALKYLIDENE COMPLEXES FOR Z SELECTIVE OLEFIN METATHESIS | SOD1, ZRANB2, ZCCHC8 | KMT2A 2188/4885MCL1 899/4885DAO 1807/4885 |
| US-20160009746-A1 | TUNGSTEN OXO ALKYLIDENE COMPLEXES FOR Z SELECTIVE OLEFIN METATHESIS | SOD1, ZRANB2, ZCCHC8 | KMT2A 2188/4885MCL1 899/4885DAO 1807/4885 |
| US-20100069406-A1 | ASPARTYL PROTEASE INHIBITORS | BACE1, CHRM1, CHRM2 | KMT2A 1765/4885MCL1 3991/4885DAO 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.